Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mirna-9-5p compound in the preparation of chronic pain diagnostic markers and therapeutic drugs

A technology of drugs and pharmaceutical dosage forms, applied in the field of biomedicine

Inactive Publication Date: 2018-11-09
XUZHOU MEDICAL COLLEGE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Purpose of the invention: the technical problem to be solved by the present invention is to overcome the deficiency of chronic pain drugs in the prior art, through in-depth research on miRNA, on the basis of the original use of miRNA-9-5p, and through a large number of experimental screening, miRNA is developed -9-5p new use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mirna-9-5p compound in the preparation of chronic pain diagnostic markers and therapeutic drugs
  • Application of mirna-9-5p compound in the preparation of chronic pain diagnostic markers and therapeutic drugs
  • Application of mirna-9-5p compound in the preparation of chronic pain diagnostic markers and therapeutic drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] 1. Preparation of complete Freund's adjuvant (CFA) chronic arthritis pain model:

[0021] SPF grade male Kunming male mice of 6 weeks were selected under isoflurane anesthesia, and 10 μl of sterile complete Freund's adjuvant (CFA; Sigma Company) was injected intradermally at two points around the left hind foot metatarsal joint. This injection concentration can induce arthritis. 24 hours after injection, thermal and mechanical pain thresholds decreased and could be maintained for more than 3 weeks, and they were regarded as qualified mice for chronic pain modeling.

[0022] Pain behavior monitoring: Thermal hyperalgesia: Place the plexiglass box on a 3mm thick glass plate, and use thermal radiation stimulation according to the Hargreaves method to irradiate the mouse's sole close to the glass plate. Record the time from the beginning of irradiation to the appearance of the mouse's foot lifting, and the cut-off time is 20s. Each animal was measured 3 times, and the ave...

Embodiment 2

[0036] Example 2 miRNA-9-5p inhibitor treatment of chronic pain animal experiments

[0037] 1. Modeling and grouping:

[0038] SPF grade male Kunming male mice of 6 weeks were selected under isoflurane anesthesia, and 40 μl of sterile complete Freund's adjuvant was intradermally injected at two points around the left hind foot metatarsal joint. This injection concentration can induce arthritis. 24 hours after injection, thermal and mechanical pain thresholds decreased and could be maintained for more than 3 weeks, and they were used as qualified mice for modeling; 20 mice were set up in the miRNA-9-5p intervention treatment group and 20 mice in the PBS-injected model control group .

[0039] 2. Experimental method:

[0040] Intrathecal injection of miRNA-9-5p inhibitor intervention treatment group in vivo: After mice were anesthetized with isoflurane, miRNA-9-5p antisense nucleotide (25 μM) (miR-9-inhibitor) was injected three times to down-regulate miRNA -9-5p expression, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of the miRNA-9-5p compound in the preparation of clinical diagnostic markers for chronic pain diseases and the preparation of medicines for treating chronic pain. The present invention screens through a large number of experiments, and the experimental results show that the expression of miRNA-9-5p in the blood of patients with chronic pain is down-regulated, and the occurrence and formation of chronic pain can be significantly inhibited by up-regulating miRNA-9-5p, and the blood clinical samples of patients with chronic pain can be further improved. Quantitative analysis was performed, showing that miRNA‑9‑5p can serve as a marker of chronic pain development.

Description

technical field [0001] The invention relates to a new application of microRNA molecules, in particular to a new application of miRNA-9-5p, and belongs to the technical field of biomedicine. Background technique [0002] MicroRNA (miRNA) is a newly discovered small 18-22bp single-stranded RNA molecule that regulates gene expression at the post-transcriptional level. miRNA is involved in various biological processes such as cell differentiation, apoptosis and metabolism, and the abnormality of this regulatory process can cause a variety of diseases. Chronic pain is one of the most common clinical diseases that endanger human health and reduce people's quality of life, and has become a hot issue in clinical and basic scientific research. Central neurons (such as spinal cord, dorsal root and trigeminal nerve) are important parts that regulate the occurrence of chronic pain, and the plasticity changes of neurons in these parts lead to central sensitization is the key to the form...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/113A61K48/00A61P29/00A61P19/02
Inventor 郝凌云潘志强薛洲亚张铭李国芳
Owner XUZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com